Dear Colleagues,

The number of potential therapeutic targets for treating cardiovascular (CV) disease is growing as our understanding of its molecular principles is increased. Recent advances in CV pharmacology research have raised interest in vascular biology and further strengthen the interplay between clinical and translational investigations. For example, SGLT2i, originally developed to treat diabetes, is now currently being investigated for a wide range of other diseases, including heart failure and chronic renal disease. In addition, anticoagulants and antiplatelet drugs, where there was once a one-size fit approach, are now being abandoned in favor of patient-tailored therapies. Evidence is now emerging on new biochemical pathways and innovative cholesterol-lowering drugs. Therefore, the aim of this issue is to raise awareness among physicians on the latest advances in CV therapy.

In this Special Issue, we will focus on, and be interested in, but are not limited to, receiving manuscripts in one or more of the following areas:

(A) Updates in Heart Failure therapy
(B) Translational and therapeutic implications of new molecular pathways 
(C) Personalizing antithrombotic treatment – when one size does not fit all
(D) New horizons in treating dyslipidemia
(E) Expert reviews on the latest and ongoing RCTs on cardiovascular drugs
(F) Emerging therapy of cardiomyopathies (i.e., Hypertrophic Cardiomyopathy, Transthyretin Cardiac Amyloidosis)
(G) Pharmacokinetics and pharmacodynamics features of new cardiovascular drugs
(H) Antiarrhythmic Drugs in Atrial Fibrillation

Prof. Vincenzo Russo and Luigi Falco

Guest Editors